دورية أكاديمية
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.
| العنوان: | Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. |
|---|---|
| المؤلفون: | Meagher NS; School of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia., Gorringe KL; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Victoria, Australia., Wakefield M; The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.; Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne, Victoria, Australia., Bolithon A; School of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia., Pang CNI; School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, New South Wales, Australia.; Bioinformatics Unit, Children's Medical Research Institute, Westmead, Sydney, Australia., Chiu DS; British Columbia's Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada., Anglesio MS; British Columbia's Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada., Mallitt KA; School of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.; Centre for Big Data Research in Health, University of New South Wales Sydney, Sydney, New South Wales, Australia., Doherty JA; Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah., Harris HR; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.; Department of Epidemiology, University of Washington, Seattle, Washington., Schildkraut JM; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia., Berchuck A; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina., Cushing-Haugen KL; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington., Chezar K; Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada., Chou A; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, New South Wales, Australia.; The University of Sydney, Sydney, New South Wales, Australia., Tan A; Division of Obstetrics and Gynaecology, Medical School, University of Western Australia, Crawley, Western Australia, Australia.; Western Women's Pathology, Western Diagnostic Pathology, Wembley, Western Australia, Australia., Alsop J; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom., Barlow E; Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, New South Wales, Australia., Beckmann MW; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany., Boros J; The University of Sydney, Sydney, New South Wales, Australia.; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia., Bowtell DDL; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Victoria, Australia., Brand AH; The University of Sydney, Sydney, New South Wales, Australia.; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia., Brenton JD; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom., Campbell I; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Victoria, Australia., Cheasley D; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Victoria, Australia., Cohen J; David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California., Cybulski C; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland., Elishaev E; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Erber R; Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander Universität Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany., Farrell R; The University of Sydney, Sydney, New South Wales, Australia.; Prince of Wales Private Hospital, Randwick, New South Wales, Australia., Fischer A; Institute of Pathology and Neuropathology, Tübingen University Hospital, Tübingen, Germany., Fu Z; Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania., Gilks B; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Gill AJ; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, New South Wales, Australia.; The University of Sydney, Sydney, New South Wales, Australia., Gourley C; Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, University of Edinburgh, Edinburgh, United Kingdom., Grube M; Department of Women's Health, Tübingen University Hospital, Tübingen, Germany., Harnett PR; The University of Sydney, Sydney, New South Wales, Australia.; Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia., Hartmann A; Institute of Pathology and Neuropathology, Tübingen University Hospital, Tübingen, Germany., Hettiaratchi A; The Health Precincts Biobank (formerly the Health Science Alliance Biobank), UNSW Biospecimen Services, Mark Wainwright Analytical Centre, University of New South Wales Sydney, Sydney, New South Wales, Australia., Høgdall CK; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Huzarski T; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.; Department of Genetics and Pathology, University of Zielona Góra, Zielona Góra, Poland., Jakubowska A; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.; Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland., Jimenez-Linan M; Department of Histopathology, Addenbrooke's Hospital, Cambridge, United Kingdom., Kennedy CJ; The University of Sydney, Sydney, New South Wales, Australia.; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia., Kim BG; Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Kim JW; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea., Kim JH; Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Klett K; Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania., Koziak JM; Alberta Health Services-Cancer Care, Calgary, Alberta, Canada., Lai T; David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California., Laslavic A; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Lester J; David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California., Leung Y; Division of Obstetrics and Gynaecology, Medical School, University of Western Australia, Crawley, Western Australia, Australia.; Department of Gynaecological Oncology, King Edward Memorial Hospital, Subiaco, Western Australia, Australia.; Australia New Zealand Gynaecological Oncology Group, Camperdown, New South Wales, Australia., Li N; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Parkville Familial Cancer Centre, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Liauw W; School of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.; Cancer Care Centre, St George Hospital, Sydney, New South Wales, Australia., Lim BWX; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Linder A; Department of Obstetrics and Gynecology, Inst of Clinical Science, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden., Lubiński J; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland., Mahale S; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Mateoiu C; Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden., McInerny S; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Parkville Familial Cancer Centre, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Menkiszak J; Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland., Minoo P; Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada., Mittelstadt S; Department of Women's Health, Tübingen University Hospital, Tübingen, Germany., Morris D; St George and Sutherland Clinical School, University of New South Wales Sydney, Sydney, New South Wales, Australia., Orsulic S; David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California., Park SY; Center for Gynecologic Cancer, National Cancer Center Institute for Cancer Control, Goyang, Republic of Korea., Pearce CL; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California., Pearson JV; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Pike MC; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California.; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York., Quinn CM; The Health Precincts Biobank (formerly the Health Science Alliance Biobank), UNSW Biospecimen Services, Mark Wainwright Analytical Centre, University of New South Wales Sydney, Sydney, New South Wales, Australia., Mohan GR; Department of Gynaecological Oncology, King Edward Memorial Hospital, Subiaco, Western Australia, Australia.; Department of Gynaecological Oncology, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia.; School of Medicine, University of Notre Dame, Fremantle, Western Australia, Australia., Rao J; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Riggan MJ; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina., Ruebner M; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany., Salfinger S; Department of Gynaecological Oncology, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia., Scott CL; Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Victoria, Australia.; The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.; Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne, Victoria, Australia., Shah M; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom., Steed H; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alberta, Edmonton, Alberta, Canada.; Section of Gynecologic Oncology Surgery, North Zone, Alberta Health Services, Edmonton, Alberta, Canada., Stewart CJR; School for Women's and Infants' Health, University of Western Australia, Perth, Western Australia, Australia., Subramanian D; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Sung S; Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea.; Cancer Research Institute, Seoul National University, Seoul, Korea.; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea., Tang K; Department of Anatomical Pathology, Prince of Wales Hospital, Sydney, New South Wales, Australia., Timpson P; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia., Ward RL; The University of Sydney, Sydney, New South Wales, Australia., Wiedenhoefer R; Institute of Pathology and Neuropathology, Tübingen University Hospital, Tübingen, Germany., Thorne H; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Cohen PA; Division of Obstetrics and Gynaecology, Medical School, University of Western Australia, Crawley, Western Australia, Australia.; Department of Gynaecological Oncology, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia., Crowe P; School of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.; Department of Surgery, Prince of Wales Private Hospital, Randwick, New South Wales, Australia., Fasching PA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany., Gronwald J; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland., Hawkins NJ; School of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia., Høgdall E; Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark., Huntsman DG; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada., James PA; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Parkville Familial Cancer Centre, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Karlan BY; David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California., Kelemen LE; Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina., Kommoss S; Department of Women's Health, Tübingen University Hospital, Tübingen, Germany., Konecny GE; David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California., Modugno F; Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania.; Women's Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania.; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Park SK; Cancer Research Institute, Seoul National University, Seoul, Korea.; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.; Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, South Korea., Staebler A; Institute of Pathology and Neuropathology, Tübingen University Hospital, Tübingen, Germany., Sundfeldt K; Department of Obstetrics and Gynecology, Inst of Clinical Science, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden., Wu AH; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California., Talhouk A; British Columbia's Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Pharoah PDP; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom., Anderson L; The University of Sydney, Sydney, New South Wales, Australia.; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia., DeFazio A; The University of Sydney, Sydney, New South Wales, Australia.; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.; The Daffodil Centre, a joint venture with Cancer Council NSW, The University of Sydney, Sydney, New South Wales, Australia., Köbel M; Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada., Friedlander ML; School of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.; Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, New South Wales, Australia.; Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, New South Wales, Australia., Ramus SJ; School of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia. |
| مؤلفون مشاركون: | AOCS Group, Australian Pancreatic Genome Initiative, kConFab Investigators |
| المصدر: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Dec 15; Vol. 28 (24), pp. 5383-5395. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Denville, NJ : The Association, c1995- |
| مواضيع طبية MeSH: | Ovarian Neoplasms*/metabolism , Adenocarcinoma, Mucinous*/genetics , Adenocarcinoma, Mucinous*/diagnosis , Gastrointestinal Neoplasms*/metabolism, Female ; Humans ; Neoplasm Staging ; Carcinoma, Ovarian Epithelial/pathology ; Prognosis |
| مستخلص: | Purpose: Advanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis and lacks biomarkers to aid stage I adjuvant treatment. Differentiating primary MOC from gastrointestinal (GI) metastases to the ovary is also challenging due to phenotypic similarities. Clinicopathologic and gene-expression data were analyzed to identify prognostic and diagnostic features. Experimental Design: Discovery analyses selected 19 genes with prognostic/diagnostic potential. Validation was performed through the Ovarian Tumor Tissue Analysis consortium and GI cancer biobanks comprising 604 patients with MOC (n = 333), mucinous borderline ovarian tumors (MBOT, n = 151), and upper GI (n = 65) and lower GI tumors (n = 55). Results: Infiltrative pattern of invasion was associated with decreased overall survival (OS) within 2 years from diagnosis, compared with expansile pattern in stage I MOC [hazard ratio (HR), 2.77; 95% confidence interval (CI), 1.04-7.41, P = 0.042]. Increased expression of THBS2 and TAGLN was associated with shorter OS in MOC patients (HR, 1.25; 95% CI, 1.04-1.51, P = 0.016) and (HR, 1.21; 95% CI, 1.01-1.45, P = 0.043), respectively. ERBB2 (HER2) amplification or high mRNA expression was evident in 64 of 243 (26%) of MOCs, but only 8 of 243 (3%) were also infiltrative (4/39, 10%) or stage III/IV (4/31, 13%). Conclusions: An infiltrative growth pattern infers poor prognosis within 2 years from diagnosis and may help select stage I patients for adjuvant therapy. High expression of THBS2 and TAGLN in MOC confers an adverse prognosis and is upregulated in the infiltrative subtype, which warrants further investigation. Anti-HER2 therapy should be investigated in a subset of patients. MOC samples clustered with upper GI, yet markers to differentiate these entities remain elusive, suggesting similar underlying biology and shared treatment strategies. (©2022 The Authors; Published by the American Association for Cancer Research.) |
| References: | BMC Cancer. 2016 Feb 04;16:55. (PMID: 26847345) Int J Gynecol Cancer. 2019 May 15;:. (PMID: 31097512) Histopathology. 2020 Jul;77(1):26-34. (PMID: 31782197) Clin Cancer Res. 2020 Oct 15;26(20):5400-5410. (PMID: 32737030) Int J Gynecol Cancer. 2018 Mar;28(3):493-499. (PMID: 29466254) Angiogenesis. 2019 Aug;22(3):397-410. (PMID: 30993566) Gynecol Oncol. 2020 Mar;156(3):552-560. (PMID: 31902686) N Engl J Med. 2022 Jul 7;387(1):9-20. (PMID: 35665782) Gynecol Oncol. 2018 Sep;150(3):527-533. (PMID: 30054102) N Engl J Med. 2020 Jun 18;382(25):2419-2430. (PMID: 32469182) Transl Oncol. 2022 Jan;15(1):101266. (PMID: 34794033) Int J Gynecol Pathol. 2005 Jan;24(1):4-25. (PMID: 15626914) Ann Oncol. 2020 Sep;31(9):1240-1250. (PMID: 32473302) Am J Surg Pathol. 2003 Jul;27(7):985-93. (PMID: 12826891) Int J Gynecol Cancer. 2019 May 2;:. (PMID: 31048403) PLoS One. 2013 Apr 19;8(4):e61565. (PMID: 23620766) J Exp Clin Cancer Res. 2018 Jul 24;37(1):166. (PMID: 30041673) Cancer Lett. 2022 Mar 1;528:59-75. (PMID: 34958892) Mod Pathol. 2019 Dec;32(12):1834-1846. (PMID: 31239549) Anticancer Res. 2001 Jul-Aug;21(4B):2983-7. (PMID: 11712798) Int J Gynecol Pathol. 2010 Mar;29(2):99-107. (PMID: 20173494) Gynecol Oncol Rep. 2019 Mar 27;28:109-115. (PMID: 30997376) Int J Clin Exp Pathol. 2014 Jun 15;7(7):4222-30. (PMID: 25120802) Mod Pathol. 2009 Jun;22(6):786-96. (PMID: 19329940) N Engl J Med. 2011 May 12;364(19):1817-25. (PMID: 21561347) Lancet Oncol. 2011 Oct;12(11):1071-80. (PMID: 21616717) J Clin Pathol. 2007 Jun;60(6):622-6. (PMID: 16822880) Arch Pathol Lab Med. 2021 Jun 1;145(6):687-691. (PMID: 32649220) J Natl Compr Canc Netw. 2021 Feb 02;19(2):191-226. (PMID: 33545690) Am J Surg Pathol. 2000 Nov;24(11):1447-64. (PMID: 11075847) J Natl Cancer Inst. 2019 Jan 1;111(1):60-68. (PMID: 29718305) PLoS One. 2016 Apr 20;11(4):e0153844. (PMID: 27096160) N Engl J Med. 2010 Nov 11;363(20):1938-48. (PMID: 21067385) J Ovarian Res. 2021 Feb 14;14(1):33. (PMID: 33583413) Am J Surg Pathol. 2002 Feb;26(2):139-52. (PMID: 11812936) J Pathol. 2013 Jan;229(1):111-20. (PMID: 22899400) Gynecol Oncol. 2019 Jun;153(3):541-548. (PMID: 31005287) Br J Cancer. 2005 Mar 14;92(5):929-34. (PMID: 15756260) Obstet Gynecol. 2019 Dec;134(6):1253-1259. (PMID: 31764736) N Engl J Med. 2019 Mar 28;380(13):1256-1266. (PMID: 30917260) Sci Rep. 2016 Sep 16;6:33366. (PMID: 27632935) Virchows Arch. 2021 May;478(5):885-891. (PMID: 33009577) Curr Treat Options Oncol. 2021 Nov 13;22(12):114. (PMID: 34773517) Nat Commun. 2019 Sep 2;10(1):3935. (PMID: 31477716) BMC Cell Biol. 2013 Mar 19;14:17. (PMID: 23510049) Cancer Sci. 2013 Apr;104(4):423-30. (PMID: 23331552) Cancer. 2011 Feb 1;117(3):554-62. (PMID: 20862744) Eur J Cancer. 2021 Mar;145:158-167. (PMID: 33485079) Clin Cancer Res. 2020 Oct 15;26(20):5411-5423. (PMID: 32554541) |
| معلومات مُعتمدة: | P30 CA008748 United States CA NCI NIH HHS |
| تواريخ الأحداث: | Date Created: 20221012 Date Completed: 20221216 Latest Revision: 20240530 |
| رمز التحديث: | 20240530 |
| مُعرف محوري في PubMed: | PMC9751776 |
| DOI: | 10.1158/1078-0432.CCR-22-1206 |
| PMID: | 36222710 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1557-3265 |
|---|---|
| DOI: | 10.1158/1078-0432.CCR-22-1206 |